ERBB2 and breast cancer: To understand whether or not epigenetic regulation via remodeling of chromatin may be used as an anti-cancer therapy in breast cancers, we evaluated four FDA-approved HDACi in luminal, HER2-enriched and TNBC breast cancer subtypes, as well as breast epithelial normal cell.